Cargando…
Third- and Late Line Treatments of Metastatic Gastric Cancer: Still More to Be Done
In recent years, advances of anticancer and supportive therapies have determined a gradual improvement in survival rates and patients’ general conditions in metastatic gastric cancer (mGC), allowing them to receive further treatments. The choice of treatment is driven by performance status, age, sta...
Autores principales: | Mare, Marzia, Memeo, Lorenzo, Colarossi, Cristina, Giuffrida, Dario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497544/ https://www.ncbi.nlm.nih.gov/pubmed/36135075 http://dx.doi.org/10.3390/curroncol29090506 |
Ejemplares similares
-
Cancer Stem Cell Biomarkers Predictive of Radiotherapy Response in Rectal Cancer: A Systematic Review
por: Mare, Marzia, et al.
Publicado: (2021) -
Medullary Carcinoma of the Gastrointestinal Tract: Report on Two Cases with Immunohistochemical and Molecular Features
por: Colarossi, Cristina, et al.
Publicado: (2021) -
Hippo pathway dysregulation in gastric cancer: from Helicobacter pylori infection to tumor promotion and progression
por: Messina, Beatrice, et al.
Publicado: (2023) -
Large cell neuroendocrine carcinoma (LCNEC) of the urinary bladder: a case report
por: Colarossi, Cristina, et al.
Publicado: (2013) -
Potential Role of Activating Transcription Factor 5 during Osteogenesis
por: Vicari, Luisa, et al.
Publicado: (2016)